The aim of the study is to estimate the pension costs incurred for patients with musculoskeletal disorders (MDs) and specifi cally with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in Italy between 2009 and 2012. We analyzed the database of the Italian National Social Security Institute (Istituto Nazionale Previdenza Sociale i.e. INPS) to estimate the total costs of three types of social security benefi ts granted to patients with MDs, RA and AS: disability benefi ts (for people with reduced working ability), disability pensions (for people who cannot qualify as workers) and incapacity pensions (for people without working ability). We developed a probabilistic model with a Monte Carlo simulation to estimate the total costs for each type of benefi t associated with MDs, RA and AS. We also estimated the productivity loss resulting from RA in 2013. From 2009 to 2012 about 393 thousand treatments were paid for a total of approximately €2.7 billion. The annual number of treatments was on average 98 thousand and cost in total €674 million per year. In particular, the total pension burden was about €99 million for RA and €26 million for AS. The productivity loss for AR in 2013 was equal to €707,425,191 due to 9,174,221 working days lost. Our study is the fi rst to estimate the burden of social security pensions for MDs based on data of both approved claims and benefi ts paid by the national security system. From 2009 to 2012, in Italy, the highest indirect costs were associated with disability pensions (54% of the total indirect cost), followed by disability benefi ts (44.1% of cost) and incapacity pensions (1.8% of cost). In conclusion, MDs are chronic and highly debilitating diseases with a strong female predominance and very signifi cant economic and social costs that are set to increase due to the aging of the population.
n INTRODUCTION M usculoskeletal conditions (MSCs) are among the most widespread diseases that affect people of all ages and ethnic groups, causing disabilities and often handicaps. As a consequence, they represent one of the main expense items for the healthcare service and social security system. A sample study on the Italian adult population (1) revealed that about 27% of the sample had some MDs. Another study (2) estimated that in Europe 103 million people are affected by these diseases which are one of the leading causes for disability. The defi nition of MDs is generic, as it includes a variety of different conditions that cause pain or discomfort in bones, joints, muscles or surrounding structures. ic diseases, which accounted for 1.2% of the gross domestic product and increased by 24% from 1997 to 2003. Another study on RA conducted by Leardini (4) in 2002 estimated that in Italy indirect costs vary on average from € 2100 for class I to € 17,000 for class IV per patient. Turchetti et al. (5) in 2014 estimated for RA a total cost of € 3.5 billion (€2.4 billion for direct costs and € 1.1 billion for indirect costs) and €740 million due to total patient productivity loss which translates in €2831 per patient.The objective of our study was to estimate the number of benefits provided and the associated pension costs incurred by the community for MSCs (it should be reminded that in Italy the social security system is funded by the state The latest report of the National Observatory on the Use of Medicines (OsMED) (7) shows that in Italy the burden for antitumor necrosis factor-a biologic drugs, which are also utilized to treat the abovementioned diseases, account for 3% of the pharmaceutical expenditure. We will focus in particular on three types of benefits provided by INPS: the disability benefit (DB) granted to workers with reduced working capacity, the incapacity pension (IP) for workers unable to work, and the disability pension (DP) granted to citizens unable to work and to support themselves. We also estimated the costs due to the loss of productivity caused by absenteeism of patients affected by RA, because out of these three diseases it is the one for which the highest number of benefits were provided. 
Disability benefit
It is a financial benefit for all categories of workers registered with INPS (mainly private sector employees and self-employed workers) with a working capacity reduced to less than one-third due to physical or mental illness, who applied for it after having paid social security contributions for five years three of wich in the last five years. The applicant is not required to cease work. The allowance is paid for a period of three years and can be renewed for further 3-year periods. After three consecutive awards, the disability allowance is confirmed automatically. This type of pension is funded and paid by INPS.
Incapacity pension
It is a financial benefit for all categories of workers registered with INPS (mainly private sector employees and self-employed workers) who applied for it after having paid social security contributions for five years three of wich in the last five years and were confirmed to be in a state of have of absolute and permanent inability to work. Retirement from work is mandatory. This type of pension is funded and paid by INPS.
Disability pension
The Italian Constitution (art. 38) provides that citizens unable to work and to support themselves, even if not belonging to any workers' category, are entitled to receive income-support allowances and benefit from a DP granted by the social security system. This type of pension is funded by the taxpayer and paid by INPS.
Italian National Social Security Institute (INPS) data
The estimate of the benefits granted is based on the claims approved by INPS (8) (9) (10) and the total benefits provided in a single year (11 The economic burden of musculoskeletal disorders on the Italian social reported as one of the disabling pathologies after an assessment on the state of the physical and mental health of the applicant conducted by the INPS medical committee and the approval of the application based on the presence of one or more disabling diseases. Figure 1 shows that MSCs account for the third group of diseases in terms of approved claims for DB and the tenth cause for IP from 2001 to 2012. The estimate of the costs per type of benefit was conducted on the basis of the average monthly values per kind of scheme (11) ( Table I) .
Estimate of applicable allowances
Estimate of applicable allowances for disability benefits and disability pensions As provided for by Italian laws (12, 13) , the DB is granted for a three-year period and may be extended for further 3-year periods. This framework makes it possible to develop a method to estimate applicable benefits based on their eligible periods by adding the approved claims of a given disease i in a year t to the claims approved in the previous two years, as expressed by the following formula (Eq. 1):
Approved t-i (1) Figure 2 -Linear regression model with total disability benefit estimated (independent variable) and total disability benefit provided (dependent variable). R 2 =0.975.
The reliability of this method is demonstrated in Figure 2 , where a linear regression model with total estimated DBs as independent variable and total DBs actually granted as dependent variable shows a coefficient of determination (R 2 ) equal to 0.975. These results demonstrate that the method is able to estimate the benefits provided with an extremely low error rate. The IP is extended for life. The estimate of applicable benefits for IP is based on the assumption that the percentage distribution of approved claims and benefits provided is basically the same. This assumption proves to be correct by comparing the percentage distribution of applicable estimated disability benefits and the percentage distribution of approved claims (Figure 3 ). The average difference per year between the two is 0.2 percentage points corresponding to 1.8% with respect to the distribution of the estimated benefits provided.Therefore, the available data on approved claims make it possible to obtain an estimate of the applicable benefits, using the following formula (Eq. 2): where Applicable i,t is the number of benefits provided for disease i in year t, Applicable t is the total number of benefits of year t and %Approved i,t is the percentage value of the approved claims for disease i in year t out of the total approved claims. The estimates of total benefits for these two categories were then broken down according to the percentage distribution indicated in Table I and multiplied by the average annual amounts on the assumption that total benefits paid and MSDs have the same percentage distributions per kind of scheme.
Estimate of current benefits for disability pension
To estimate this kind of allowance the same method identified for IP can be applied, but for 2011 and 2012 only, as the information about approved claims for MSDs in other years is not available. Therefore, the value is equal to the percentage of approved claims for MSCs out of the total of approved claims multiplied by the DP granted for all diseases. For 2009 and 2010 the total applicable benefits were estimated through DB and IP trends. The percentage of granted DP for MSCs in a year is indicated in Table II  and was Once granted DP percentages are available, the benefits provided for MSCs can be obtained by applying the same methodology used for 2011 and 2012.
Statistical analysis: Monte Carlo simulation
The parameters used to estimate the costs incurred by INPS for social security benefits were assumed to be subject to some degree of uncertainty. For this reason, a Monte Carlo simulation was performed. It consists in a simultaneous variation of the parameters used in the model according to a probability distribution (14). This simulation generated a series of observations of the phenomenon under examination in order to evaluate the range of variation. First of all we have identified the sources of parameter uncertainty: i) total benefits provided; ii) percentage distribution per kind of scheme; iii) yearly values per kind of scheme. We assigned a probability distribution to each parameter. The distributions were selected to comply with the characteristics of this data (15) . For the benefits provided and the yearly values we assigned a gamma distribution, generally used for values that have the constraint of non-negativity, while we used the beta distribution for the percentage distributions per kind of scheme that assume values between 0 and 1. Once we assigned probability distributions to the parameters, the uncertainty was extended to the whole model through a Monte Carlo simulation. For each run of the model, the software extracted a random value for each parameter according to the assigned distribution and recorded the results of each simulation. The model was then iterated with 10,000 simulations. We applied this method to obtain the confidence intervals and more robust estimates of the current benefits and the associated costs.
Calculation of costs due to the loss of productivity
The loss of productivity of workers affected by RA was estimated on the basis of the data made available by the National Institute of Statistics (Istat) (16, 17) , the Center for Social Investment Studies (Censis) (18) and various scientific publications (4, 19) . As shown in Table III , this information was intended to estimate the remuneration of a single work day and the number of lost work days, broken down by gender, disease stage and job. These data refer to different years, therefore we assume that they are unchanged as of 2013, which is the reference year for the estimate of costs associated with the loss of productivity.
n RESULTS Figure 4A reports the estimates of the benefits provided. DP reports 228,372 applicable benefits in the four years under study, followed by DB with 161,154 and IP with 4252 benefits. The trends of DB and IP are rather stable, while for DP there was a decrease in benefits paid mirroring the trend of the total benefits provided for DP (Table   N  o As far as the estimate of costs is concerned, Figure 4B shows that DP generated an expenditure of €1.4 billion in the four years under study, followed by DB with about €1.2 billion and IP with about €49 million. The trends are rather stable for IP, while a slight decrease is reported for DB over 2010 and 2011 and for DP the total costs fell by 32% from 2009 to 2012. The estimate of the two specific conditions shows that RA is the disease with the highest number of benefits provided, approximately 13,000 from 2009 to 2012 ( Figure  4C ), along with the highest costs, amounting to about €99 million ( Figure 4D ). As far as AS is concerned, about 3400 benefits were provided over this four-year period for a total of approximately €26 million. Figure 5A reports the sum of the estimates of the three benefits in terms of costs and granted allowances. Between 2009 and 2012 the estimated average benefits provided per year were about 98,445 which were worth about €674 million, while the total benefits provided over the same four years were 393,778 with a total cost of €2.6 billion. The cost breakdown indicated in Figure 5B shows that 54% of MSC costs are generated by DP, about 44% by DB and a little less than 2% by IP. Table IV reports the results of the cost esti- mates for the loss of productivity. By comparing the two genders, the female population affected by RA is five times greater than the male one, considering that women represent about 72% of the people affected by the disease. 74% of them are employed. Overall, the estimate reports about 134 thousand employed people affected by RA, 22 thousand males and 112 thousand females. Lost work days were nearly 9 million (1.4 million for males and 7.3 million for females) amounting to about €704 million (€193 million for males and €511 for females). Consequently the productivity loss per employed patient was €8840 for males and €4552 for female.
Estimate of social security costs Estimate of benefits provided and costs for disability benefits, disability pensions and incapacity pensions

Estimate of total costs
Estimate of costs due to the loss of productivity
CONCLUSIONS
The MSCs involve quite relevant economic and social costs due to the chronic nature of these diseases. This study is the first attempt an estimate of pension costs for MSCs using data of claims approved and benefits provided by INPS. These costs are particularly significant due to the benefits provided. In particular, DPs with an average of about 57,000 benefits provided translated into a cost of €364 million, followed by DBs with 40,000 benefits provided with a cost of €298 million and 1000 IPs with a cost of €12 million. The productivity loss for RA involves a total of approximately 134,000 people, 84% of whom are women, for a total of about 9 million lost working days and a cost of slightly over €700 million. However our study has some limitations. It was not possible to consider in estimate of DBs the survival of patients with MSCs between the time when the claims were accepted and the following three years in which the benefit was granted. The IPs provided were estimated without taking into account the different probabilities of survival for the pathology groups classified according to INPS which involve some differences between the percentage distributions for pathological groups of approved claims and the distribution of the benefits provided. The estimate of benefits for DP 
ORIGINAL ARTICLE
The economic burden of musculoskeletal disorders on the Italian social has the same limits of the estimation of IP and is also based on data referring to two single years. The DB and IP provided by INPS do not include all the existing job categories (mainly private sector employees and self-employed workers, for example the public sector workers were not considered). Finally, the data used for the calculations on the loss of productivity refer to different years.
In conclusion, MSCs are highly debilitating and chronic diseases with a strong female prevalence. Despite some pension costs were reduced in recent years, they still require a considerable use of funds that could even increase due to the aging population. In order to prevent and minimize the consequences of this scenario, more appropriate prescriptions and a faster access to innovative treatments would reduce the costs incurred by the social security system and improve the effectiveness of interventions, although Italy compared with the rest of the EU countries has the greatest delay in terms of availability of innovative technologies (20) . 
